VA to offer new ketamine-based nasal spray to help combat depression

news

Editor's Note: This article by Patricia Kime originally appeared on Military.com, a leading source of news for the military and veteran community.

The newest FDA-approved medication to treat severe depression, a nasal spray based on the anesthetic (and misused hallucinogenic party drug) ketamine, will soon be available to veterans treated within the Department of Veterans Affairs.


In a move that may help thousands of former service members with depression that has not improved with other treatments, VA officials announced Tuesday that the department's doctors are now authorized to prescribe Spravato, the brand name for esketamine, a molecular variation of ketamine.

The decision to offer a drug hailed by many as a breakthrough in treatment for its speedy results -- often relieving symptoms in hours and days, not weeks -- shows the VA's "commitment to seek new ways to provide the best health care available for our nation's veterans," Secretary Robert Wilkie said in a release.

"We're pleased to be able to expand options for Veterans with depression who have not responded to other treatments," Wilkie added.

The treatment will be available to veterans based on a physician's assessment and only will be administered to patients who have tried at least two antidepressant medications and continue to have symptoms of major depressive disorder.

An estimated 16 million Americans have had at least one major episode of depression, and of those, 1 in 3 are considered treatment-resistant. In the veteran population of 20 million, the estimated diagnosis rate of depression is 14 percent -- up to 2.8 million veterans. Between one-third and half of those veterans may be treatment-resistant.

The lack of effective medications for difficult-to-treat patients prompted the Food and Drug Administration to place esketamine on a fast track, expediting its review of the drug to ensure that it went to patent as soon as safely possible, according to administration officials.

"Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA's drug approval process, including a robust discussion with our external advisory committees, were important in our decision to approve this treatment," said Dr. Tiffany Farchione, acting director of the FDA's Center for Drug Evaluation and Research Division of Psychiatry Products, in a release.

As with any other medication, there are risks. Spravato carries a boxed warning for side effects that include misuse, the reason it is administered under a doctor's supervision. The list of side effects includes sedation and blood pressure spikes and disassociation, such as feelings of physical paralysis and out-of-body experiences. It also can cause suicidal thoughts and behaviors.

Acknowledging the dangers, FDA made esketamine available only through a restricted distribution system.

A veteran prescribed Spravato would inhale the nasal spray at a medical facility while under supervision of a medical provider, and would be monitored for at least two hours after receiving the dose. A typical prescription includes twice-weekly doses the first month, followed by a single dose weekly or biweekly as needed. Spravato cannot be dispensed for home use.

Spravato is made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is the first major antidepressant medication to hit the market in 30 years.

This article originally appeared on Military.com

More articles from Military.com:

SEE ALSO: The VA Is Eyeing Ketamine As An Emergency Treatment For Patients At High Suicide Risk

Spc. Michael T. Osorio (U.S. Army photo)

A third U.S. service member within a week has died in a non-combat related incident, the Pentagon announced on Wednesday.

Army Spc. Michael T. Osorio, 20, died on April 23 in Taji, Iraq, a Defense Department release says.

No information was immediately available on how Osorio died. The incident is under investigation.

Read More Show Less
Iran's Foreign Minister Mohammad Javad Zarif sits for an interview with Reuters in New York, New York, U.S. April 24, 2019. (Reuters/Carlo Allegri)

NEW YORK (Reuters) - Iranian Foreign Minister Mohammad Javad Zarif does not believe U.S. President Donald Trump wants war with Iran, but he told Reuters on Wednesday that Trump could be lured into a conflict.

"I don't think he wants war," Zarif said in an interview at the Iranian mission to the United Nations in New York. "But that doesn't exclude him being basically lured into one."

The White House did not immediately respond to a request for comment on Zarif's remarks.

Read More Show Less

Philippine President Rodrigo Duterte hates many things. Drugs. Gambling. God. Now we can add the global scourge of Canada to his hit list.

Read More Show Less

Ben Affleck is gearing up to direct and star in Ghost Army, a new World War II movie about a secret U.S. Army unit made up of artists, actors, advertising agents, and engineers who had one mission: to dupe Hitler.

And that's exactly what they did.

Read More Show Less
Capt. Paul Sikkema. Photo: Arapahoe Sheriff's Department

An Air Force Academy ethics instructor was arrested on Wednesday and charged with internet luring of a child.

Read More Show Less